Rankings
▼
Calendar
KNSA FY 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$220M
+471.2% YoY
Gross Profit
$197M
89.6% margin
Operating Income
$10M
4.4% margin
Net Income
$183M
83.3% margin
EPS (Diluted)
$2.60
Cash Flow
Operating Cash Flow
$6M
Free Cash Flow
$6M
Stock-Based Comp.
$25M
Balance Sheet
Total Assets
$460M
Total Liabilities
$64M
Stockholders' Equity
$396M
Cash & Equivalents
$123M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$220M
$39M
+471.2%
Gross Profit
$197M
$29M
+570.0%
Operating Income
$10M
-$157M
+106.2%
Net Income
$183M
-$158M
+216.1%
← Q4 2021
All Quarters
Q1 2022 →